Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Patients With Spinal Muscular Atrophy

NCT05115110 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05115110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05115110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Patients With Spinal Muscular Atrophy
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
June 2, 2022
Completion date
October 28, 2026
Enrollment
97 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy (sma)